Optimal treatments and outcome measures of palmoplantar pustulosis: A systematic review and network meta‐analysis‐based comparison of treatment efficacy

医学 荟萃分析 置信区间 掌跖脓疱病 随机对照试验 优势比 梅德林 分级(工程) 系统回顾 随机效应模型 内科学 物理疗法 皮肤病科 银屑病 土木工程 政治学 法学 工程类
作者
Takemichi Fukasawa,Takashi Yamashita,Atsushi Enomoto,Asako Yoshizaki‐Ogawa,Kiyoshi Miyagawa,Shinichi Sato,Ayumi Yoshizaki
出处
期刊:Journal of The European Academy of Dermatology and Venereology [Wiley]
卷期号:38 (2): 281-288 被引量:5
标识
DOI:10.1111/jdv.19499
摘要

Few studies have made direct comparisons between treatments for palmoplantar pustulosis (PPP); therefore, it is difficult to select the best treatment for each patient. To determine the best therapy and to compare reported measures of efficacy in clinical trials of systemic treatments for PPP in this systematic review and network meta-analysis. Six databases were used to perform database search on 10 July 2022. Randomized controlled trials (RCTs) were identified through a systematic literature search. The titles and abstracts of articles were initially screened for inclusion by two authors independently using our predetermined criteria. The full texts of selected articles were then independently assessed for inclusion in a blinded fashion. Disagreement between the authors was resolved by consensus. Data were abstracted in duplicate. Random-effects model was accepted to perform network meta-analysis. Assessed Grading of Recommendations Assessment, Development and Evaluation certainty of evidence were performed according to the PRISMA guidelines. The analysis was completed in July 2022. The primary outcome was the change of PPP Area and Severity Index (PPPASI) from baseline and the secondary outcome was the achievement of PPPASI-50 response. Seven RCTs with 567 patients were included. Guselkumab 100 mg was the one with the highest probability of reaching the proposed outcomes (mean difference [MD], -8.00; 95% confidence interval [CI], 4.88-11.11), while the achievement of PPPASI-50 response did not show a significant difference (odds ratio [OR], 3.79; 95% CI, 0.51-28.37). Guselkumab 200 mg was next to 100 mg of reaching the proposed outcomes (MD, -4.71; 95% CI, 2.12-7.30), while the achievement of PPPASI-50 response did not show a significant difference (OR, 2.34; 95% CI, 0.48-11.43). Network meta-analysis showed guselkumab 100 mg was the treatment with the highest probability of reaching both PPPASI and PPPASI-50 outcomes. Absolute PPPASI may be more appropriate as an outcome than PPPASI-50.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
hai完成签到,获得积分10
刚刚
hua发布了新的文献求助10
刚刚
zls发布了新的文献求助10
1秒前
文艺月亮发布了新的文献求助10
1秒前
abcdefg发布了新的文献求助10
1秒前
1+1发布了新的文献求助20
1秒前
杨启军完成签到,获得积分10
2秒前
易安发布了新的文献求助10
2秒前
ling完成签到,获得积分10
2秒前
思源应助ylq采纳,获得10
3秒前
Nothing发布了新的文献求助10
3秒前
史永桂发布了新的文献求助10
4秒前
4秒前
有魅力敏完成签到,获得积分10
4秒前
4秒前
5秒前
meimei完成签到,获得积分10
5秒前
量子星尘发布了新的文献求助10
6秒前
6秒前
领导范儿应助ling采纳,获得10
6秒前
7秒前
orixero应助自然有手就行采纳,获得10
7秒前
7秒前
7秒前
1111应助tina采纳,获得10
8秒前
华仔应助hua采纳,获得10
8秒前
福馨馨完成签到,获得积分10
8秒前
8秒前
9秒前
姜依晨关注了科研通微信公众号
9秒前
9秒前
9秒前
杨启军发布了新的文献求助10
9秒前
10秒前
柴柴子发布了新的文献求助30
10秒前
浅色墨水发布了新的文献求助10
11秒前
星辰大海应助汤振杰采纳,获得30
11秒前
11秒前
12秒前
12秒前
高分求助中
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
Christian Women in Chinese Society: The Anglican Story 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3961392
求助须知:如何正确求助?哪些是违规求助? 3507731
关于积分的说明 11137649
捐赠科研通 3240136
什么是DOI,文献DOI怎么找? 1790806
邀请新用户注册赠送积分活动 872520
科研通“疑难数据库(出版商)”最低求助积分说明 803271